Novel self-associating poly(ethylene oxide)-b-poly(ε-caprolactone) based drug conjugates and nano-containers for paclitaxel delivery

被引:68
作者
Shahin, Mostafa [1 ]
Lavasanifar, Afsaneh [1 ,2 ]
机构
[1] Univ Alberta, Fac Pharm & Pharmaceut Sci, Edmonton, AB T6G 2N8, Canada
[2] Univ Alberta, Dept Chem & Mat Engn, Edmonton, AB T6G 2V4, Canada
基金
加拿大自然科学与工程研究理事会;
关键词
Paclitaxel; Polymeric micelles; Polymer-drug conjugate; Poly(ethylene oxide)-block-poly(epsilon-caprolactone); POLYMERIC MICELLES; BLOCK-COPOLYMERS; CORE STRUCTURE; TAXOL; PRODRUGS; CT-2103; RELEASE; TAXANE; AGENTS; FORMULATIONS;
D O I
10.1016/j.ijpharm.2010.01.015
中图分类号
R9 [药学];
学科分类号
100702 [药剂学];
摘要
Poly(ethylene oxide)-block-poly(epsilon-caprolactone) (PEO-b-PCL) copolymers bearing paclitaxel (PTX) side groups on PCL (PEO-b-P(CL-PTX) were synthesized and assembled to particles of 123 nm average diameter. At 20% (w/w) PTX to polymer conjugation, PEO-b-P(CL-PTX) demonstrated only 5.0 and 6.7% PTX release after 72 h incubation at pH 7.4 and 5.0, respectively, but revealed signs of chain cleavage at pH 5.0. The cytotoxicity of PEO-b-P(CL-PTX) against MDA-MB-435 cancer cells increased as incubation time was raised from 72 to 96 h (IC50 of 680 and 475 ng/mL, respectively), but it was still significantly lower than the cytotoxicity of free PTX (IC50 of 3.5 ng/mL at 72 h). In further studies, micelles of PEO-b-PCL and those bearing benzyl or PTX on PCL were used for physical encapsulation of PTX, where maximum level of loading was achieved by PEO-b-P(CL-PTX) (2.22%, w/w). The release of PTX from this carrier was rapid; however. The in vitro cytotoxicity of physically loaded PTX was independent of carrier and similar to that of free PTX. This was attributed to the low concentration of polymers which fell below their critical micellar concentration in the cytotoxicity study. The results point to the potential of chemically tailored PEO-b-PCL for optimum PTX solubilization and delivery. (C) 2010 Elsevier B.V. All rights reserved.
引用
收藏
页码:213 / 222
页数:10
相关论文
共 39 条
[1]
[Anonymous], PHARMACOTHERAPY
[2]
Boyle D A, 1998, Clin J Oncol Nurs, V2, P141
[3]
Chen Qiang, 2003, Zhonghua Zhongliu Zazhi, V25, P190
[4]
Hydrotropic agents for study of in vitro paclitaxel release from polymeric micelles [J].
Cho, YW ;
Lee, J ;
Lee, SC ;
Huh, KM ;
Park, K .
JOURNAL OF CONTROLLED RELEASE, 2004, 97 (02) :249-257
[5]
Modeling and comparison of dissolution profiles [J].
Costa, P ;
Manuel, J ;
Lobo, S .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2001, 13 (02) :123-133
[6]
The dawning era of polymer therapeutics [J].
Duncan, R .
NATURE REVIEWS DRUG DISCOVERY, 2003, 2 (05) :347-360
[7]
Polymer conjugates as anticancer nanomedicines [J].
Duncan, Ruth .
NATURE REVIEWS CANCER, 2006, 6 (09) :688-701
[8]
Novel Taxane Formulations and Microtubule-Binding Agents in Non-Small-Cell Lung Cancer [J].
Edelman, Martin J. .
CLINICAL LUNG CANCER, 2009, 10 :S30-S34
[9]
Paclitaxel prodrugs with sustained release and high solubility in poly(ethylene glycol)-b-poly(ε-caprolactone) micelle nanocarriers:: Pharmacokinetic disposition, tolerability, and cytotoxicity [J].
Forrest, M. Laird ;
Yanez, Jaime A. ;
Remsberg, Connie M. ;
Ohgami, Yusuke ;
Kwon, Glen S. ;
Davies, Neal M. .
PHARMACEUTICAL RESEARCH, 2008, 25 (01) :194-206
[10]
HIGHLY WATER-SOLUBLE TAXOL DERIVATIVES - 2'-POLYETHYLENEGLYCOL ESTERS AS POTENTIAL PRODRUGS [J].
GREENWALD, RB ;
PENDRI, A ;
BOLIKAL, D ;
GILBERT, CW .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1994, 4 (20) :2465-2470